Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner

Nanomedicine and Nanoscale Delivery (Focus Group – NND)

Formulation of Nanosuspensions of Challenging Drugs Using Amphiphilic Janus-Dendrimers as Stabilizing Agents

Sami Nummelin – Senior Researcher, BioHybrid Materials, Aalto University; Mauri Kostiainen – Full Professor, BioHybrid Materials, Aalto University; Vera Moura – Director, Basinnov Life Sciences; Ana Fortuna – Researcher and Full Assistant Professor, CIBIT - Coimbra Institute for Biomedical Imaging and Translational Research and Faculty of Pharmacy, University of Coimbra; Luís Bimbo – Assistant Professor, Center for Neuroscience and Cell Biology - Centre for Innovative Biomedicine and Biotechnology and Faculty of Pharmacy, University of Coimbra
Introduction: Poor solubility and instability continue to limit the bioavailability of many drugs [1]. Nanosuspensions offer a way to address these challenges, but their performance relies heavily on the choice of stabiliser [2]. Conventional agents often struggle to maintain long‑term stability across different drug types [2]. Amphiphilic Janus dendrimers (JDs) provide tunable architectures and have already shown superior stabilisation in drug suspensions [3]. This project develops JD‑based nanosuspensions for ceftazidime, ampicillin and glucagon to establish structure–activity relationships and improve formulation stability.

Learning Objectives:

  • Understand how Janus dendrimer structural features influence nanosuspension stabilisation.
  • Learn how formulation strategies vary for weak acids, weak bases and peptides using JD stabilisers.
  • Identify how JD architecture affects dissolution, stability and in vivo pharmacokinetic behaviour.